<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02218489</url>
  </required_header>
  <id_info>
    <org_study_id>KPI-121-C-003</org_study_id>
    <nct_id>NCT02218489</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease</brief_title>
  <acronym>Maui</acronym>
  <official_title>A Phase II, Double-Masked, Randomized, Vehicle-Controlled Study to Evaluate the Effect of KPI-121 0.25% Ophthalmic Suspension on Signs and Symptoms of Inflammatory Meibomian Gland Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kala Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kala Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the efficacy and safety of KPI-121
      ophthalmic suspension compared to vehicle (placebo) in subjects with signs and symptoms of
      inflammatory meibomian gland disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, multicenter, double-masked, randomized, vehicle-controlled,
      parallel-group study designed to evaluate the efficacy and safety of KPI-121 ophthalmic
      suspension versus vehicle in subjects with signs and symptoms of inflammatory meibomian gland
      disease. The product will be studied over 28 days, with 1-2 drops instilled in each eye four
      times daily (QID).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Posterior Lid Margin Hyperemia</measure>
    <time_frame>Day 29</time_frame>
    <description>Comparison of posterior lid margin hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Discomfort</measure>
    <time_frame>Day 22 to Day 29</time_frame>
    <description>Comparison of ocular discomfort between the KPI-121 0.25% ophthalmic suspension group and the vehicle group</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">206</enrollment>
  <condition>Blepharitis</condition>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle (placebo) dosed QID for up to 30 days in subjects with inflammatory meibomian gland disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KPI-121 0.25% Ophthalmic Suspension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>KPI-121 0.25% Ophthalmic Suspension dosed QID for up to 30 days in subjects with inflammatory meibomian gland disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KPI-121</intervention_name>
    <description>KPI-121 drug product will be supplied in 0.25% strength as a suspension in opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arm will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.</description>
    <arm_group_label>KPI-121 0.25% Ophthalmic Suspension</arm_group_label>
    <other_name>KPI-121 0.25% Ophthalmic Suspension</other_name>
    <other_name>Loteprednol etabonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>The vehicle control has the same composition as KPI-121 0.25% ophthalmic suspension except it does not contain LE. The vehicle is essentially isotonic and is buffered to maintain pH 5.0 - 7.0. It is a sterile, aqueous solution supplied in the same white, low-density polyethylene plastic dropper bottle with the same white, controlled-drop polyethylene tip and white polypropylene closure as KPI-121 0.25% ophthalmic suspension.</description>
    <arm_group_label>Vehicle</arm_group_label>
    <other_name>KPI-121 0.25% Vehicle</other_name>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Have a documented clinical diagnosis of inflammatory meibeomian gland disease in both eyes.

        Exclusion Criteria:

          -  Known hypersensitivity/contraindication to study product(s) or components.

          -  Be currently receiving treatment for glaucoma, have history of or current glaucoma, or
             an IOP over 21mmHg at Visit 1 (Screening) or Visit 2 (Randomization).

          -  Be unwilling to discontinue warm compress therapy, lid expression, or lid massage 14
             days prior to Day 1 and for the duration of the study.

          -  Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in
             judgment of Investigator could confound study assessments or limit compliance;
             severe/serious systemic disease or uncontrolled medical condition that in judgment of
             Investigator could confound study assessments or limit compliance; or have been
             exposed to an investigational drug within the 30 days prior to screening.

          -  Have had ocular surgery in the past 90 days or require ocular surgery during the
             study.

          -  In the opinion of Investigator or study coordinator, be unwilling or unable to comply
             with study protocol or unable to successfully instill eye drops.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Abrams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abrams Eye Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Damien Goldberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wolstan &amp; Goldberg Eye Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jodi Luchs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Shore Eye Center, LLP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kelly Nichols, OD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UAB School of Optometry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Rauchman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Valley Eye Medical Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Sall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sall Research Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Sheppard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Eye Consultants</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Tauber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tauber Eye Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB School of Optometry</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sall Research Medical Center</name>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <zip>90701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Valley Eye Medical Group</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolstan &amp; Goldberg Eye Associates</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tauber Eye Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Shore Eye Center, LLP</name>
      <address>
        <city>Wantagh</city>
        <state>New York</state>
        <zip>11793</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abrams Eye Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Eye Consultants</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2014</study_first_submitted>
  <study_first_submitted_qc>August 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2014</study_first_posted>
  <disposition_first_submitted>October 19, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>October 19, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 20, 2016</disposition_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Corticosteroid</keyword>
  <keyword>Meibomian Gland Disease</keyword>
  <keyword>Blepharitis</keyword>
  <keyword>Eyelid</keyword>
  <keyword>Ocular Discomfort</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

